Cortney Caudill was appointed Senior Vice President, Chief Operating Officer of Halozyme Therapeutics effective October 1, 2025. She had served as the Company's Senior Vice President, Chief Operations Officer since October 2023.
Prior to joining Halozyme, from 2019 to October 2023, Ms. Caudill served in roles of increasing responsibility at Aeglea Biotherapeutics, Inc., a biotechnology company, including Vice President of Manufacturing, Senior Vice President, Technical Operations and, most recently, Chief Product Officer. From 2002 to 2018, she held operational roles of increasing responsibility at various life sciences companies, including Cambrex Bioscience, Vaxgen, Inc., Genentech, Vetter Pharma International, Samsung Biologics, Baxalta and Eaulife NA.
She received her B.S. degree in biology and her B.A. degree in psychology from the University of Texas.